A Dose-Escalation Study for Patients With Advanced Cancer
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of
advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).